⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843128 | 0.79 | — | — | |
| SCHEMBL9842819 | 0.75 | — | — | |
| SCHEMBL1392324 | 0.74 | — | — | |
| SCHEMBL1454856 | 0.74 | — | — | |
| SCHEMBL4028671 | 0.74 | — | — | |
| SCHEMBL10444579 | 0.74 | — | — | |
| SCHEMBL17816366 | 0.72 | — | — | |
| SCHEMBL7874059 | 0.72 | — | — | |
| SCHEMBL7776223 | 0.72 | — | — | |
| SCHEMBL6663492 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651643-A4 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC (BM) | 2008-10-08 | — | — | EP | claimed |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC | 2007-11-08 | — | — | US | claimed |
| US-7253164-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2007-08-07 | — | — | US | claimed |
| EP-1651643-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2006-05-03 | — | — | EP | claimed |
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | IRM LLC | 2005-09-08 | — | — | US | claimed |
| WO-2005011611-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2005-02-10 | — | — | WO | claimed |
| EP-1064253-A1 | ANTI-TUMOUR AGENTS | AstraZeneca AB (SE) | 2001-01-03 | — | — | EP | claimed |
| EP-0994853-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | Atherogenics, Inc. (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1999048857-A1 | ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 1999-09-30 | — | — | WO | claimed |
| WO-1998051662-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | ATHEROGENICS, INC. (US) | 1998-11-19 | — | — | WO | claimed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | disclosed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | disclosed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | disclosed |
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | disclosed |
| US-10696845-B2 | Energy-sensitive resin composition | TOKYO OHKA KOGYO CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-5332757-A | Enzyme inhibitors | ZENECA LIMITED (GB) | 1994-07-26 | — | — | US | disclosed |
| US-5304549-A | Control or prevention of degenerative joint diseases | HOFFMANN-LA ROCHE INC. (US) | 1994-04-19 | — | — | US | disclosed |
| EP-0353047-A2 | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents | Sankyo Company Limited (JP) | 1990-01-31 | — | — | EP | disclosed |
| EP-0339562-A1 | Benzopyran compound and its pharmaceutical use | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-11-02 | — | — | EP | disclosed |
| EP-0281842-A1 | Aminomethyl-heterocycles | BAYER AG (DE) | 1988-09-14 | — | — | EP | disclosed |